Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on July 13, 2017. The filing reports the entry into a Material Definitive Agreement for a registered direct offering of common stock and a concurrent private placement of warrants.
Key Financial Metrics and Transaction Details
- Securities Issued: 6,191,500 shares of Common Stock and warrants to purchase 4,643,625 shares (0.75 warrants per share).
- Offering Price: $1.15 per share (combined price for one share and one warrant).
- Warrant Terms: Exercise price of $1.41 per share; exercisable beginning six months after issuance; expire on the fifth anniversary of the initial exercise date.
- Expected Gross Proceeds: Approximately $7.1 million.
- Expected Net Proceeds: Approximately $6.5 million (after deducting placement agent fees and offering expenses).
- Placement Agent Fee: 6% of gross proceeds paid to Maxim Group LLC.
- Use of Proceeds: Funding research and development activities, working capital, and general corporate purposes.
Material Changes and Transaction Structure
The Company entered into a Securities Purchase Agreement with accredited investors. The transaction involves a registered direct offering under a shelf registration statement (File No. 333-211705) and a concurrent private placement of warrants exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. The closing of the offerings is expected on July 19, 2017.
Guidance, Outlook, and Risks
- Lock-Up Period: The Company agreed not to issue or announce the issuance of Common Stock or equivalents for 75 days following the closing.
- Beneficial Ownership Limitation: Warrant holders cannot exercise if it would result in beneficial ownership exceeding 4.99% (extendable to 9.99% with 61 days' notice).
- Risks: Forward-looking statements regarding the settlement and receipt of proceeds are subject to risks, including the ability to satisfy closing conditions. Actual results may differ materially from expectations.
Important Facts for Investor Verification
- Verify the actual closing date and final net proceeds received, as the filing states these are expected values.
- Confirm the dilution impact of the 6,191,500 new shares and the potential 4,643,625 warrant shares on existing shareholders.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant (Exhibit 4.1) for specific covenants and adjustment mechanisms.
- Note that the filing explicitly states the registrant is Trovagene, Inc., despite the metadata request referencing Cardiff Oncology, Inc.